Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8314741 | 0.89 | RXRA (0.49) | ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL8310205 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL11133454 | 0.83 | HTT (0.45) | ALDH1A1MAPK1SLC6A3KEAP1FFAR1 | |
| SCHEMBL27576865 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TDP1L3MBTL1KMT2ATSHR | |
| SCHEMBL7587208 | 0.79 | ALDH1A1 (0.47) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27739393 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6271777 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL22321972 | 0.78 | TSHR (0.41) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL5310161 | 0.77 | TSHR (0.44) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL11330873 | 0.76 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227734-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282862-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-29 | — | — | EP | disclosed |
| CN-101353312-B | Phenylglycine derivatives synthesis | HENGDIAN GROUP JIAYUAN CHEMICAL INDUSTRY CO., LTD. (CN) | 2011-12-14 | — | — | CN | disclosed |
| CN-101353312-A | Phenylglycine derivatives synthesis | HENGDIAN GROUP JIAYUAN CHEMIST (CN) | 2009-01-28 | — | — | CN | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| EP-1299379-A2 | LACTAM METALLOPROTEASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002004416-A2 | LACTAM METALLOPROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| CN-1057296-C | Morpholine tachykinin receptor antagonists, their preparation and use | MERCK & CO INC (US) | 2000-10-11 | — | — | CN | disclosed |
| EP-0934262-A1 | BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017639-A1 | BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1998-04-30 | — | — | WO | disclosed |
| CN-1142819-A | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO INC (US) | 1997-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | ALDH1A1 1477/4885TDP1 2834/4885MAPK1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.